Ironwood Pharmaceuticals Profile

USD 0.23  1.53%

Sale by Lawrence Olanoff of 3725 shares of Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Inc insider trading alert for sale of class a common stock by Lawrence Olanoff, the corporate stakeholder, on March 17, 2018. This event was filed by Ironwood Pharmaceuticals with SEC on 2015-09-09. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Ironwood Pharmaceuticals Summary

Ironwood Pharmaceuticals Inc (IRWD) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 730 people. Ironwood Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 2.32 B. Ironwood Pharmaceuticals Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 136.9 M outstanding shares of which 17.74 M shares are currently shorted by private and institutional investors with about 11.73 trading days to cover. Ironwood Pharmace currently holds about 221.42 M in cash with (99.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.47.
Check Ironwood Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Ironwood Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Ironwood Pharmaceuticals Against Markets

Current Ratings

Ironwood Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 41% 
Equity ratings for Ironwood Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts. Ironwood Pharmaceuticals operates under Drugs - Generic classification in USA and traded on NASDAQ exchange. It employs 730 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameIronwood Pharmaceuticals Inc
Co-Founder, CEO and DirectorPeter HechtView All
Thematic ClassificationObamacare RepealView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address301 Binney Street
CIK Number01446847.0
IndustryPharmaceutical Products
Contact Number617 621 7722
CurrencyUSD - US Dollar


Ironwood Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
Ironwood Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Ironwood Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Ironwood Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.22May 8, 2017
Ironwood Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Ironwood Pharmaceuticals Corporate Directors
Terrance McGuire Independent Director, MBA
Meredith Kaya Director - Investor Relations
Julie McHugh Independent Director